Cargando…
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications
Intraperitoneal (IP) delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models. Its advantage over intravenous (IV) administration was supported initially by observational studies in treating recurrent ovarian cancer and eventually by better outcome...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019271/ https://www.ncbi.nlm.nih.gov/pubmed/35582028 http://dx.doi.org/10.20517/cdr.2020.116 |